Bicocca Open Archive

Logo unimib boa
GORI, ANDREA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 16.234
AS - Asia 7.726
EU - Europa 6.075
SA - Sud America 1.245
AF - Africa 195
Continente sconosciuto - Info sul continente non disponibili 13
OC - Oceania 7
Totale 31.495
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.177
SG - Singapore 2.843
CN - Cina 1.548
HK - Hong Kong 1.199
RU - Federazione Russa 1.064
IT - Italia 1.015
BR - Brasile 930
CA - Canada 899
VN - Vietnam 889
SE - Svezia 774
IE - Irlanda 732
DE - Germania 677
UA - Ucraina 456
GB - Regno Unito 318
FR - Francia 270
IN - India 244
FI - Finlandia 205
BD - Bangladesh 178
AT - Austria 160
TR - Turchia 145
AR - Argentina 118
IQ - Iraq 103
ID - Indonesia 94
MX - Messico 83
DK - Danimarca 82
ZA - Sudafrica 69
SA - Arabia Saudita 58
JP - Giappone 56
PK - Pakistan 52
NL - Olanda 50
KR - Corea 49
RO - Romania 48
EC - Ecuador 43
ES - Italia 42
BE - Belgio 41
CO - Colombia 40
PL - Polonia 38
UZ - Uzbekistan 38
PH - Filippine 37
VE - Venezuela 32
CL - Cile 28
MA - Marocco 24
TN - Tunisia 20
JO - Giordania 19
PY - Paraguay 19
AE - Emirati Arabi Uniti 17
CH - Svizzera 16
IR - Iran 16
NP - Nepal 16
CZ - Repubblica Ceca 15
ET - Etiopia 15
EG - Egitto 14
IL - Israele 14
KE - Kenya 14
MY - Malesia 14
OM - Oman 14
PA - Panama 13
PE - Perù 13
CR - Costa Rica 12
JM - Giamaica 12
AZ - Azerbaigian 11
LB - Libano 11
LT - Lituania 11
UY - Uruguay 11
TH - Thailandia 10
BO - Bolivia 9
EU - Europa 9
HN - Honduras 9
KZ - Kazakistan 9
AL - Albania 8
BH - Bahrain 8
DO - Repubblica Dominicana 8
GR - Grecia 8
PT - Portogallo 8
BG - Bulgaria 7
AU - Australia 6
SN - Senegal 6
DZ - Algeria 5
MD - Moldavia 5
PS - Palestinian Territory 5
SY - Repubblica araba siriana 5
TW - Taiwan 5
BZ - Belize 4
HR - Croazia 4
NG - Nigeria 4
AO - Angola 3
BB - Barbados 3
BY - Bielorussia 3
KG - Kirghizistan 3
KH - Cambogia 3
ML - Mali 3
SI - Slovenia 3
SV - El Salvador 3
TT - Trinidad e Tobago 3
A2 - ???statistics.table.value.countryCode.A2??? 2
BW - Botswana 2
CI - Costa d'Avorio 2
EE - Estonia 2
GT - Guatemala 2
KW - Kuwait 2
Totale 31.446
Salva come PNG Salva come JPEG
Città #
Singapore 1.610
Ann Arbor 1.412
Woodbridge 1.344
Fairfield 1.231
Hong Kong 1.182
Ashburn 1.177
Houston 1.027
San Jose 830
Chandler 745
Dublin 716
Toronto 649
Jacksonville 568
Wilmington 546
Seattle 478
Frankfurt am Main 436
Cambridge 435
New York 404
Dearborn 319
Princeton 280
Ho Chi Minh City 268
Milan 261
Chicago 248
Los Angeles 233
Beijing 222
The Dalles 221
Santa Clara 214
Dallas 199
Hanoi 197
Nanjing 151
Altamura 133
Lauterbourg 133
Lawrence 133
Shanghai 125
Moscow 122
Vienna 122
Lachine 110
Buffalo 103
São Paulo 98
Council Bluffs 94
Dong Ket 83
Hefei 83
Helsinki 76
San Diego 75
Boardman 74
Ottawa 57
Jakarta 54
Andover 51
Fremont 50
London 49
Munich 47
Nanchang 47
Tokyo 45
Galati 43
Seoul 42
Hebei 41
Brussels 40
Shenyang 40
Baghdad 39
Nuremberg 35
Rio de Janeiro 35
Orem 34
Salt Lake City 34
Johannesburg 32
Guangzhou 31
Montreal 31
Tashkent 31
Denver 30
Hangzhou 30
Norwalk 29
Da Nang 25
Falls Church 25
Rome 25
Columbus 24
Florence 24
Tianjin 24
Changsha 23
Kent 23
Phoenix 23
Amsterdam 22
Warsaw 22
Haiphong 21
Jeddah 21
Pune 21
Atlanta 20
Riyadh 19
Washington 19
Boston 18
Chennai 18
Cuauhtémoc 18
New Delhi 18
Brasília 17
Brooklyn 17
Edmonton 17
Zhengzhou 17
Amman 16
Belo Horizonte 16
Dhaka 16
Stockholm 16
Biên Hòa 15
Elk Grove Village 15
Totale 20.779
Salva come PNG Salva come JPEG
Nome #
Specific immunosuppressive role of nanodrugs targeting calcineurin in innate myeloid cells 445
Characterizing non-tuberculous mycobacteria infection in bronchiectasis 409
Similar success rates but lower incidence of telaprevir-related rash in HIV/HCV coinfected as compared to HCV-monoinfected patients treated with triple anti-HCV therapy 350
Impact of orotracheal intubation and mechanical ventilation on the microbiota of the lung in the development of Ventilator- Associated Pneumonia 328
Effects of autologous stem cell transplantation in HIV: searching for the origins of viral replication in settings of profound CD4(+) T cell depletion 324
Primary Whipple disease of the Central Nervous System presenting with rhombencephalitis 320
A case of cerebrospinal fluid viral escape on a dual antiretroviral regimen: Worth the risk? 319
Brief Report: Peripheral Monocyte/Macrophage Phenotypes Associated with the Evolution of Cognitive Performance in HIV-Infected Patients 317
The CCR5Δ32 allele is not a major predisposing factor for severe H1N1pdm09 infection 316
Comment on "Management of infections in cirrhotic patients: Report of a consensus conference" S Fagiuoli et al. [Dig Liver Dis 2014;46:204-212] 315
HIV testing: A must for patients with inflammatory bowel disease 314
Brachial and central blood pressure in HIV-infected subjects 310
Strategies to limit immune-activation in HIV patients 302
Risk of chronic kidney disease among patients developing mild renal impairment during tenofovir-containing antiretroviral treatment 301
Prospective immune dynamics during the first 24 weeks of efavirenz based-antiretroviral therapy in HIV-1-infected subjects, according to CD4+ T-cell counts at presentation: The IMMUNEF clinical trial 294
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL 293
Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART 291
Customization of LC-MS-based proteomic workflows for biological studies in the clinical field 287
Durability of lopinavir/ritonavir monotherapy in individuals with viral load ≤50 copies/ml in an observational setting 287
Combination versus sequential monotherapy in chronic HBV infection: A mathematical approach 284
Untargeted Mass Spectrometry Approach to Study SARS-CoV-2 Proteins in Human Plasma and Saliva Proteome 282
Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: Data from the ICONA cohort 277
ECMO: An alternative support for acute respiratory failure caused by tuberculosis? 276
Incidence and predictors of cardiovascular disease, chronic kidney disease, and diabetes in HIV/HCV-coinfected patients who achieved sustained virological response 273
Evaluation of adhesion molecules and immune parameters in HIV-infected patients treated with an atazanavir/ritonavir- compared with a lopinavir/ritonavir-based regimen 273
CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: An observational cohort study 271
Risk of Liver Enzyme Elevation During Treatment With Ritonavir-Boosted Protease Inhibitors Among HIV-Monoinfected and HIV/HCV-Coinfected Patients 266
A case of classic neuromyelitis optica (Devic's syndrome) triggered by pegylated-interferon α 262
Microbiological testing of adults hospitalised with community-acquired pneumonia: an international study 262
Combination antifungal therapy for invasive mold infections among pediatric patients with hematological malignancies: Data from a real-life case-series 259
Specific prebiotics modulate gut microbiota and immune activation in HAART-naive HIV-infected adults: Results of the "cOPA" pilot randomized trial 258
Plasma Proteomic Variables Related to COVID-19 Severity: An Untargeted nLC-MS/MS Investigation 257
Cytomegalovirus coinfection is associated with an increased risk of severe non-AIDS-defining events in a large cohort of HIV-infected patients 254
miRNA-218 targets lipin-1 and glucose transporter type 4 genes in 3T3-L1 cells treated with lopinavir/ritonavir 253
Neurocognitive Impairment in HIV-Infected Naïve Patients with Advanced Disease: The Role of Virus and Intrathecal Immune Activation 247
Lung cryptococcosis in a treated HIV-1-infected patient with suppressed viral load and past disseminated cryptococcosis: Relapse or late IRIS? 246
Ultrasonographic backscatter of the carotid artery wall in patients with HIV infection: a pilot study 245
Unmasking tuberculosis in the era of antiretroviral treatment 245
Estimating minimum adult HIV prevalence: A cross-sectional study to assess the characteristics of people living with HIV in Italy 245
Arterial structure and function in AIDS patients: the impact of renal damage. 244
Focal bone lesions in hiv-positive patient treated with tenofovir 243
Metabolic syndrome in human immunodeficiency virus-positive subjects: prevalence, phenotype, and related alterations in arterial structure and function 240
Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus 240
Nontuberculous Mycobacteria in Noncystic Fibrosis Bronchiectasis 239
Changes in subcutaneous adipose tissue microRNA expression in HIV-infected patients 238
Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program 238
Use of CXCR4-antagonist for haematopoietic stem cell mobilization in HIV-infected patients with haematological malignancies 236
Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study 236
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 236
Untargeted mass spectrometry approach to study SARS-CoV-2 proteins and characterize human plasma and saliva proteome in COVID-19 patients. 233
KIR-HLA genotypes in HIV-infected patients lacking immunological recovery despite effective antiretroviral therapy 233
Mycobacterium tuberculosis Beijing family: Analysis of the epidemiological and clinical factors associated with an emerging lineage in the urban area of Milan 232
Neurocognitive impairment in HIV infected naïve patients: the role of genetic polymorphisms, viral changes and intrathecal immune activation 229
Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice 229
Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count 224
Immunosuppressant Treatment in Rheumatic Musculoskeletal Diseases Does Not Inhibit Elicitation of Humoral Response to SARS-CoV-2 Infection and Preserves Effector Immune Cell Populations 223
Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort 223
Liver enzyme elevation during darunavir-based antiretroviral treatment in HIV-1-infected patients with or without hepatitis c coinfection: Data from the ICONA foundation cohort 223
Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials 223
Effects of antiretroviral therapy on endothelial function in HIV patients. 222
The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: Results of a 3-year cohort study 221
Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: A prospective international cohort study 221
Influence of hospitalization upon diagnosis on the risk of tuberculosis clustering 219
Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy 219
Long-term durability of tenofovir-based antiretroviral therapy In relation to the Co-administration of other drug classes in routine clinical practice 217
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 214
High rates of sustained virological response despite premature discontinuation of directly acting antivirals in HCV-infected patients treated in a real-life setting 214
Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study 213
HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: Results of a randomized phase II exploratory clinical trial 212
Under representation of the inhibitory KIR3DL1 molecule and the KIR3DL1+/BW4+ complex in HIV exposed seronegative individuals 209
Structural and functional alterations of large arteries in HIV patients and their relationships with metabolic syndrome. 207
Characterization of immune failure by monocyte activation phenotypes in HIV-infected patients receiving antiretroviral therapy 206
Access to treatment for HBV infection and its consistency with 2008 European guidelines in a multicentre cross-sectional study of HIV/HBV co-infected patients in Italy 206
Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: A multilevel analysis 204
High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects Data from the ICONA Foundation Cohort 202
HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial 201
A case of mild pulmonary disease due to Mycobacterium shimoidei with a favorable outcome 201
Determinants of use of the fixed dose combination emtricitabine/rilpivirine/tenofovir (Eviplera) in HIV-infected persons receiving care in Italy 201
Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure 200
Early changes in adhesion molecules expression and endothelial function in patients initiating ART with Atazanavir or Lopinavir 199
Role of serum free light chains in predicting HIV-associated non-Hodgkin lymphoma and Hodgkin's lymphoma and its correlation with antiretroviral therapy 199
Evaluation of the prognostic value of impaired renal function on clinical progression in a large cohort of HIV-infected people seen for care in Italy 197
Impact of previous ART and of ART initiation on outcome of HIV-associated tuberculosis 197
Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: Week 48 results from the randomised, double-blind, non-inferiority SAILING study 196
Risk of severe non AIDS events is increased among patients unable to increase their CD4 + T-cell counts >200+/μl despite effective HAART 195
Impact of HAART with protease inhibitors treatment on carotid wall structure in HIV patients. 195
Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure 195
Antimicrobial therapy duration: A major matter in the management of severe infections 194
An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy 194
Risk of clinical progression among patients with immunological nonresponse despite virological suppression after combination antiretroviral treatment 192
To the editor 192
Low-level viraemia, measured as viraemia copy-years, as a prognostic factor for medium-long-term all-cause mortality: A MASTER cohort study 192
Pregnancy outcomes among ART-naive and ART-experienced HIV-positive women: data from the ICONA foundation study group, years 1997-2013 191
Inflammatory cytokines drive CD4+ t-cell cycling and impaired responsiveness to interleukin 7: Implications for immune failure in HIV disease 189
Beyond the gut bacterial microbiota: The gut virome 189
Discontinuation of initial antiretroviral therapy in clinical practice: Moving toward individualized therapy 188
Plasma proteomic signatures related to COVID-19 disease severity by an untargeted nLC-ESI-MS/MS approach 187
Treatment discontinuation in HIV-1-infected individuals starting their first-line HAART after 2008: data from the ICONA Foundation Study Cohort 187
Latent tuberculosis infection in psoriasis and other dermatological immunomediated diseases: A combined approach by QuantiFERON®-TB Gold and tuberculin skin tests 187
Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons 187
Totale 24.270
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.081
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.081
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021176 0 0 0 0 0 0 0 0 0 0 0 176
2021/20221.509 40 103 212 146 73 135 61 124 72 118 116 309
2022/20232.909 369 803 233 291 188 471 31 167 210 28 72 46
2023/20242.086 43 72 97 81 283 552 427 80 145 49 35 222
2024/20254.704 285 525 358 211 390 156 241 170 571 748 366 683
2025/202610.631 1.129 635 815 1.005 1.237 612 1.463 522 929 993 1.004 287
Totale 32.441